Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma
Open Access
- 3 February 2007
- journal article
- clinical trial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 13 (4) , 423-432
- https://doi.org/10.1016/j.bbmt.2006.11.011
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myelomaBlood, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Outcome of unrelated transplants in patients with multiple myelomaBone Marrow Transplantation, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignanciesBlood, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myelomaBlood, 2002
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990